The invention provides antibodies or antigen binding fragments thereof to
DR5 and HER-2. The antibodies and/or antigen binding fragments thereof
comprise variant CDRs comprising highly restricted amino acid sequence
diversity. The invention also provides these polypeptides as fusion
polypeptides to heterologous polypeptides such as at least a portion of
phage or viral coat proteins, tags and linkers. In addition, compositions
and methods of use for treatment of cancer and immune related conditions
are provided.